{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:24:56Z","timestamp":1765887896295,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T00:00:00Z","timestamp":1495065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670333"],"award-info":[{"award-number":["81670333"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470387"],"award-info":[{"award-number":["81470387"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00059-017-4563-4","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T05:51:19Z","timestamp":1495086679000},"page":"338-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Use of tolvaptan vs. furosemide in older patients with heart failure","Einsatz von Tolvaptan vs. Furosemid bei \u00e4lteren Patienten mit Herzinsuffizienz"],"prefix":"10.1007","volume":"43","author":[{"given":"W.\u2011l.","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2011b.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.\u2011l.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.\u2011f.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"issue":"6","key":"4563_CR1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","volume":"19","author":"PJ Hauptman","year":"2013","unstructured":"Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D et\u00a0al (2013) Clinical course of patients with Hyponatremiaand decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J\u00a0Card Fail 19(6):390\u2013397","journal-title":"J Card Fail"},{"issue":"1","key":"4563_CR2","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.3390\/ijms17010105","volume":"17","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kinugawa K (2016) Urine aquaporin-2: a promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure. Int J Mol Sci 17(1):E105","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4563_CR3","first-page":"1","volume":"11","author":"AH Zulkifli","year":"2016","unstructured":"Zulkifli AH, Suridanda DS (2016) Tolvaptan: a novel diuretic in heart failure management. J\u00a0Tehran Heart Cent 11(1):1\u20135","journal-title":"J Tehran Heart Cent"},{"issue":"1","key":"4563_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","volume":"25","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T (2007) Tolvaptan, an orally active vasopressin V(2)-receptor antagonist \u2013 pharmacology and clinical trials. Cardiovasc Drug Rev 25(1):1\u201313","journal-title":"Cardiovasc Drug Rev"},{"issue":"3","key":"4563_CR5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/0300060513480089","volume":"41","author":"I Sakaida","year":"2013","unstructured":"Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y et al (2013) Efficacy and safety of a\u00a014-day administration of tolvaptan in the treatment ofpatients with ascites in hepatic oedema. J\u00a0Int Med Res 41(3):835\u2013847","journal-title":"J Int Med Res"},{"key":"4563_CR6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CMAR.S90169","volume":"8","author":"B Thajudeen","year":"2016","unstructured":"Thajudeen B, Salahudeen AK (2016) Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives. Cancer Manag Res 8:105\u2013114","journal-title":"Cancer Manag Res"},{"issue":"2","key":"4563_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/hepr.12769","volume":"47","author":"H Kawaratani","year":"2016","unstructured":"Kawaratani H, Fukui H, Yoshiji H (2016) Treatment for cirrhotic ascites. Hepatol Res 47(2):166. doi:\n                        10.1111\/hepr.12769","journal-title":"Hepatol Res"},{"key":"4563_CR8","first-page":"1","volume-title":"Polycystic kidney disease","author":"S Guler","year":"2015","unstructured":"Guler S, Cimen S, Hurton S, Molinari M (2015) Diagnosis and treatment modalities of symptomatic polycystic kidney disease. In: Li X (ed) Polycystic kidney disease. Codon Publications, Brisbane, pp\u00a01\u201310"},{"issue":"3","key":"4563_CR9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A et al (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a\u00a0position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31(3):337\u2013348","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"4563_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","volume":"67","author":"K Kimura","year":"2016","unstructured":"Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H et\u00a0al (2016) Early\u00a0administration\u00a0of\u00a0tolvaptan\u00a0preserves\u00a0renal\u00a0function\u00a0in\u00a0elderly\u00a0patients\u00a0with\u00a0acutedecompensated\u00a0heart\u00a0failure. J\u00a0Cardiol 67(5):399\u2013405","journal-title":"J Cardiol"},{"key":"4563_CR11","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0735-1097(16)31427-9","volume":"67","author":"M Kinoshita","year":"2016","unstructured":"Kinoshita M, Okayama H, Kawamura G, Shigematsu T, Takahashi T, Kawada Y et\u00a0al (2016) Favorable effect of early administration of tolvaptanin elderlypatients with repeat hospitalizations for acute decompensated heart failure. J\u00a0Am Coll Cardiol 67(13, Supplement):1426","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4563_CR12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","volume":"22","author":"Y Matsue","year":"2016","unstructured":"Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y et\u00a0al (2016) Clinical effectiveness of tolvaptan in patientswith acute heartfailure and renal dysfunction. J\u00a0Card Fail 22(6):423\u2013432","journal-title":"J Card Fail"},{"issue":"S1","key":"4563_CR13","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M (2011) Efficacy and safety of tolvaptan in heart failure patientswith volume overload despite the standard treatmentwith conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(S1):S33\u2013S45. doi:\n                        10.1007\/s10557-011-6304-x","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"4563_CR14","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00380-015-0775-9","volume":"31","author":"Y Uemura","year":"2016","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S et\u00a0al (2016) Clinical benefit of tolvaptan in patients with acute decompensatedheart failure and chronic kidney disease. Heart Vessel 31(10):1643\u20131649","journal-title":"Heart Vessel"},{"issue":"2","key":"4563_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","volume":"61","author":"Y Matsue","year":"2013","unstructured":"Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A et al (2013) Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J\u00a0Cardiol 61(2):169\u2013174","journal-title":"J Cardiol"},{"key":"4563_CR16","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M et al (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a\u00a0double-blind, randomized trial. Circulation 107:2690\u20132696","journal-title":"Circulation"},{"issue":"5","key":"4563_CR17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jjcc.2016.02.004","volume":"67","author":"SR Goldsmith","year":"2016","unstructured":"Goldsmith SR (2016) A new approach to treatment of acute heart failure. J\u00a0Cardiol 67(5):395\u2013398","journal-title":"J Cardiol"},{"issue":"7","key":"4563_CR18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cardfail.2013.05.003","volume":"19","author":"AD Foebel","year":"2013","unstructured":"Foebel AD, Heckman GA, Ji K, Dubin JA, Turpie ID, Hussack P et al (2013) Heart\u00a0failure \u2013 related\u00a0mortality\u00a0and\u00a0hospitalization\u00a0inthe\u00a0year\u00a0following\u00a0admission\u00a0toa\u00a0long-term\u00a0carefacility:the\u00a0geriatric\u00a0outcomes\u00a0and\u00a0longitudinal\u00a0decline\u00a0in\u00a0heart failure\u00a0(GOLD-HF)\u00a0study. J\u00a0Card Fail 19(7):468\u2013477","journal-title":"J Card Fail"},{"issue":"6","key":"4563_CR19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10741-015-9503-x","volume":"20","author":"B Xiong","year":"2015","unstructured":"Xiong B, Huang Y, Tan J, Yao Y, Wang C, Qian J et al (2015) The short-term and long-term effects of tolvaptan in patientswith heart failure: a\u00a0meta-analysis of randomized controlled trials. Heart Fail Rev 20(6):633\u2013642","journal-title":"Heart Fail Rev"},{"issue":"2","key":"4563_CR20","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C et al (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium andpotassium excretion in human heart failure. Am J Physiol Renal Physiol 290(2):F273\u2013F278","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"4563_CR21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/AC.69.6.1000008","volume":"69","author":"E Abo-Salem","year":"2014","unstructured":"Abo-Salem E, Sherif K, Dunlap S, Prabhakar S (2014) Potential aetiologies and prognostic implications of worsening renal function in acute decompensated heart failure. Acta Cardiol 69(6):657\u2013663","journal-title":"Acta Cardiol"},{"issue":"3","key":"4563_CR22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10741-011-9280-0","volume":"17","author":"M Gheorghiade","year":"2012","unstructured":"Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G et al (2012) A comprehensive, longitudinal description of the in-hospitaland post-discharge clinical, laboratory, and neurohormonalcourse of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 17(3):485\u2013509","journal-title":"Heart Fail Rev"},{"key":"4563_CR23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1253\/circj.CJ-12-1328","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T et\u00a0al (2013) Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ\u00a0J 77:1208\u20131213","journal-title":"Circ J"},{"key":"4563_CR24","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ihj.2015.07.006","volume":"68","author":"E Shanmugam","year":"2016","unstructured":"Shanmugam E, Doss CR, George M, Jena A, Rajaram M, Ramaraj B et\u00a0al (2016) Effect of\u00a0tolvaptan\u00a0on acute heart failure with hyponatremia \u2013 a randomized, double blind, controlledclinical trial. Indian Heart\u00a0J 68:S15\u2013S21. doi:\n                        10.1016\/j.ihj.2015.07.006","journal-title":"Indian Heart J"},{"issue":"5","key":"4563_CR25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1536\/ihj.16-007","volume":"57","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kinugawa K, Nitta D, Komuro I (2016) Tolvaptan\u00a0reduces long-term total medical expenses and length of stay in aquaporin-defined responders. Int Heart\u00a0J 57(5):593\u2013599","journal-title":"Int Heart J"},{"key":"4563_CR26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2016.07.034","volume":"221","author":"A Eguchi","year":"2016","unstructured":"Eguchi A, Iwasaku T, Okuhara Y, Naito Y, Mano T, Masuyama T et al (2016) Long-term administration of tolvaptan increases myocardial remodelingand mortality via exacerbation of congestion in mice heart failure modelafter myocardial infarction. Int J Cardiol 221:302\u2013309","journal-title":"Int J Cardiol"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-017-4563-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4563-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T02:20:26Z","timestamp":1528856426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-017-4563-4"}},"subtitle":["Meta-analysis of randomized controlled trials","Metaanalyse randomisierter kontrollierter Studien"],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4563"],"URL":"https:\/\/doi.org\/10.1007\/s00059-017-4563-4","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"type":"print","value":"0340-9937"},{"type":"electronic","value":"1615-6692"}],"subject":[],"published":{"date-parts":[[2017,5,18]]}}}